{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:47:23Z","timestamp":1790520443472,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T00:00:00Z","timestamp":1526688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ejpb.2018.05.021","type":"journal-article","created":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T06:11:46Z","timestamp":1526710306000},"page":"21-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The effect of formulation on spray dried Sabin inactivated polio vaccine"],"prefix":"10.1016","volume":"129","author":[{"given":"Gaurav","family":"Kanojia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimko","family":"ten Have","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Brugmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Soema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henderik W.","family":"Frijlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Amorij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejpb.2018.05.021_b0005","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1590\/S0100-879X1997000600001","article-title":"Rare adverse events associated with oral poliovirus vaccine in Brazil","volume":"30","author":"Friedrich","year":"1997","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.ejpb.2018.05.021_b0010","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu. Rev. Microbiol."},{"issue":"20","key":"10.1016\/j.ejpb.2018.05.021_b0015","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","article-title":"Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication","volume":"27","author":"Minor","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2018.05.021_b0020","unstructured":"Polio Eradication and Endgame Strategic Plan 2013\u20132018, 2013. Available from: <http:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/PEESP_EN_A4.pdf>."},{"issue":"Suppl 1","key":"10.1016\/j.ejpb.2018.05.021_b0025","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1093\/infdis\/jiu128","article-title":"Affordable inactivated poliovirus vaccine: strategies and progress","volume":"210","author":"Okayasu","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"41","key":"10.1016\/j.ejpb.2018.05.021_b0030","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ejpb.2018.05.021_b0035","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/erv.09.20","article-title":"Opportunities and challenges of developing thermostable vaccines","volume":"8","author":"Chen","year":"2009","journal-title":"Expert Rev. Vaccines"},{"issue":"2\u20133","key":"10.1016\/j.ejpb.2018.05.021_b0040","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.ddtec.2008.11.001","article-title":"Drying methods for protein pharmaceuticals","volume":"5","author":"Maltesen","year":"2008","journal-title":"Drug Discov. Today Technol."},{"issue":"4","key":"10.1016\/j.ejpb.2018.05.021_b0045","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11095-009-0045-6","article-title":"Stability of protein pharmaceuticals: an update","volume":"27","author":"Manning","year":"2010","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.ejpb.2018.05.021_b0050","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1007\/s11095-014-1359-6","article-title":"Development of thermostable lyophilized inactivated polio vaccine","volume":"31","author":"Kraan","year":"2014","journal-title":"Pharm. Res."},{"issue":"7","key":"10.1016\/j.ejpb.2018.05.021_b0055","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1073\/pnas.1017334108","article-title":"Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques","volume":"108","author":"Lin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.ejpb.2018.05.021_b0060","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1073\/pnas.0800043105","article-title":"Immunization by a bacterial aerosol","volume":"105","author":"Garcia-Contreras","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.ejpb.2018.05.021_b0065","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3109\/1061186X.2014.888071","article-title":"Cellulose acetate phthalate microparticles containing Vibrio cholerae: steps toward an oral cholera vaccine","volume":"22","author":"Pastor","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2018.05.021_b0070","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-016-0566-3","article-title":"Physicochemical and preclinical evaluation of a novel buccal measles vaccine","author":"Gala","year":"2016","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/j.ejpb.2018.05.021_b0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jconrel.2011.12.039","article-title":"Towards tailored vaccine delivery: needs, challenges and perspectives","volume":"161","author":"Amorij","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2018.05.021_b0080","doi-asserted-by":"crossref","unstructured":"G. Kanojia et al., Developments in the formulation and delivery of spray dried vaccines, Hum. Vaccin. Immunother. (2017) 0.","DOI":"10.1080\/21645515.2017.1356952"},{"issue":"24","key":"10.1016\/j.ejpb.2018.05.021_b0085","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/j.vaccine.2014.02.022","article-title":"Improved poliovirus D-antigen yields by application of different Vero cell cultivation methods","volume":"32","author":"Thomassen","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ejpb.2018.05.021_b0090","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ijpharm.2016.08.022","article-title":"A design of experiment approach to predict product and process parameters for a spray dried influenza vaccine","volume":"511","author":"Kanojia","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2018.05.021_b0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2010.02.025","article-title":"A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation","volume":"144","author":"Saluja","year":"2010","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.ejpb.2018.05.021_b0100","doi-asserted-by":"crossref","first-page":"e0163109","DOI":"10.1371\/journal.pone.0163109","article-title":"The production of a stable infliximab powder: the evaluation of spray and freeze-drying for production","volume":"11","author":"Kanojia","year":"2016","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.ejpb.2018.05.021_b0105","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.vaccine.2011.02.085","article-title":"Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines","volume":"29","author":"Westdijk","year":"2011","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2018.05.021_b0110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijpharm.2016.04.067","article-title":"Evaluation of excipients for enhanced thermal stabilization of a human type 5 adenoviral vector through spray drying","volume":"506","author":"LeClair","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"4637","key":"10.1016\/j.ejpb.2018.05.021_b0115","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1126\/science.223.4637.701","article-title":"Preservation of membranes in anhydrobiotic organisms: the role of trehalose","volume":"223","author":"Crowe","year":"1984","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ejpb.2018.05.021_b0120","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.vaccine.2009.11.024","article-title":"Heat-stable measles vaccine produced by spray drying","volume":"28","author":"Ohtake","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2018.05.021_b0125","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-016-1860-1","article-title":"Stabilization of live attenuated influenza vaccines by freeze drying, spray drying, and foam drying","author":"Lovalenti","year":"2016","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.ejpb.2018.05.021_b0130","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/acs.molpharmaceut.6b00072","article-title":"Optimized formulation of a thermostable spray-dried virus-like particle vaccine against human papillomavirus","volume":"13","author":"Saboo","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2018.05.021_b0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jconrel.2016.05.012","article-title":"Thermostabilization of inactivated polio vaccine in PLGA-based microspheres for pulsatile release","volume":"233","author":"Tzeng","year":"2016","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.ejpb.2018.05.021_b0140","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1021\/ac400968q","article-title":"Isoelectric point determination of live polioviruses by capillary isoelectric focusing with whole column imaging detection","volume":"85","author":"Thomassen","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejpb.2018.05.021_b0145","unstructured":"I.H.T. Guideline, Pharmaceutical Development Q8(R2) (2008), <http:\/\/www.ich.org\/products\/guidelines\/quality\/quality-single\/article\/pharmaceutical-development.html>."},{"issue":"4","key":"10.1016\/j.ejpb.2018.05.021_b0150","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00726-007-0506-3","article-title":"Biotechnology applications of amino acids in protein purification and formulations","volume":"33","author":"Arakawa","year":"2007","journal-title":"Amino Acids"},{"issue":"10","key":"10.1016\/j.ejpb.2018.05.021_b0155","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.vaccine.2017.01.070","article-title":"Glutathione is a highly efficient thermostabilizer of poliovirus Sabin strains","volume":"35","author":"Abdelnabi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2018.05.021_b0160","first-page":"155","article-title":"Thermostability of poliovirus and measles vaccines","volume":"87","author":"Melnick","year":"1996","journal-title":"Dev. Biol. Stand."},{"issue":"1","key":"10.1016\/j.ejpb.2018.05.021_b0165","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/abbi.1997.0111","article-title":"Elucidating mechanisms of thermostabilization of poliovirus by D2O and MgCl2","volume":"342","author":"Chen","year":"1997","journal-title":"Arch. Biochem. Biophys."},{"issue":"17","key":"10.1016\/j.ejpb.2018.05.021_b0170","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.vaccine.2015.03.011","article-title":"Alternative delivery of a thermostable inactivated polio vaccine","volume":"33","author":"Kraan","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ejpb.2018.05.021_b0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/biol.1997.0118","article-title":"Studies on the loss of infectivity of live type 3 poliovaccine on storage","volume":"26","author":"Pipkin","year":"1998","journal-title":"Biologicals"},{"key":"10.1016\/j.ejpb.2018.05.021_b0180","first-page":"344","article-title":"A field based evaluation of adverse events following MenAfriVac(\u00ae)vaccine delivered in a controlled temperature chain (CTC) approach in Benin","volume":"18","author":"Steffen","year":"2014","journal-title":"Pan Afr Med J"},{"issue":"39","key":"10.1016\/j.ejpb.2018.05.021_b0185","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1016\/j.vaccine.2014.07.029","article-title":"Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants","volume":"32","author":"Verdijk","year":"2014","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.ejpb.2018.05.021_b0190","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1586\/14760584.2016.1158650","article-title":"Alternative administration routes and delivery technologies for polio vaccines","volume":"15","author":"Kraan","year":"2016","journal-title":"Expert Rev Vaccines"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118301966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118301966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T16:47:58Z","timestamp":1751647678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641118301966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":38,"alternative-id":["S0939641118301966"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.05.021","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of formulation on spray dried Sabin inactivated polio vaccine","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}